J. Chen, Yang Xiao, L. Wu, Feng-Shou Xiao, Q. Wang, J. Hong, P. Zhu
{"title":"[Ru(bpy)2(phen)]Cl2对鼻咽癌细胞的放射增敏作用","authors":"J. Chen, Yang Xiao, L. Wu, Feng-Shou Xiao, Q. Wang, J. Hong, P. Zhu","doi":"10.18869/ACADPUB.IJRR.18.3.549","DOIUrl":null,"url":null,"abstract":"Background: To investigate effect of radiosensitization of [Ru(bpy)2(phen)] Cl2 complex on nasopharyngeal carcinoma cell line CNE1 and its mechanism. Materials and Methods: Nasopharyngeal carcinoma cell line CNE1 in vitro culture was divided into control group, light irradiation group (4 Gy, 6 MV photonic line), simple metal ruthenium complex treatment group (Ru group, 100 μmol/L [Ru(bpy)2(phen)]Cl2) and metal ruthenium complex combined with radiotherapy group (Combined radiotherapy group, cells were irradiated with 4 Gy and 6 MV photons at 2 days after 100 μmol/L [Ru(bpy)2(phen)]Cl2). Results: Transcriptional level of P53 gene in combined radiotherapy group was higher than that in the other groups (P<0.001). Inhibition rate of combined radiotherapy group was higher than that of Ru group and irradiation group (P<0.001). Apoptotic rate was the highest (P<0.05) in the combined radiotherapy group, and irradiation group was higher than Ru group and control group (P<0.05). Survival rate of Ru group was lower than that of control group under the same radiation dose (P<0.05), and the radiotherapy sensitization ratio was 1.227 (Dq ratio). Conclusion: [Ru(bpy)2 (phen)]Cl2 increases the sensitivity of nasopharyngeal carcinoma cell line CNE1 to X-ray, which may be related to increase of P53 gene expression.","PeriodicalId":14498,"journal":{"name":"Iranian Journal of Radiation Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Radiosensitization of [Ru(bpy)2(phen)]Cl2 on nasopharyngeal carcinoma cells\",\"authors\":\"J. Chen, Yang Xiao, L. Wu, Feng-Shou Xiao, Q. Wang, J. Hong, P. Zhu\",\"doi\":\"10.18869/ACADPUB.IJRR.18.3.549\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: To investigate effect of radiosensitization of [Ru(bpy)2(phen)] Cl2 complex on nasopharyngeal carcinoma cell line CNE1 and its mechanism. Materials and Methods: Nasopharyngeal carcinoma cell line CNE1 in vitro culture was divided into control group, light irradiation group (4 Gy, 6 MV photonic line), simple metal ruthenium complex treatment group (Ru group, 100 μmol/L [Ru(bpy)2(phen)]Cl2) and metal ruthenium complex combined with radiotherapy group (Combined radiotherapy group, cells were irradiated with 4 Gy and 6 MV photons at 2 days after 100 μmol/L [Ru(bpy)2(phen)]Cl2). Results: Transcriptional level of P53 gene in combined radiotherapy group was higher than that in the other groups (P<0.001). Inhibition rate of combined radiotherapy group was higher than that of Ru group and irradiation group (P<0.001). Apoptotic rate was the highest (P<0.05) in the combined radiotherapy group, and irradiation group was higher than Ru group and control group (P<0.05). Survival rate of Ru group was lower than that of control group under the same radiation dose (P<0.05), and the radiotherapy sensitization ratio was 1.227 (Dq ratio). Conclusion: [Ru(bpy)2 (phen)]Cl2 increases the sensitivity of nasopharyngeal carcinoma cell line CNE1 to X-ray, which may be related to increase of P53 gene expression.\",\"PeriodicalId\":14498,\"journal\":{\"name\":\"Iranian Journal of Radiation Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Radiation Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18869/ACADPUB.IJRR.18.3.549\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Health Professions\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Radiation Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18869/ACADPUB.IJRR.18.3.549","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
Radiosensitization of [Ru(bpy)2(phen)]Cl2 on nasopharyngeal carcinoma cells
Background: To investigate effect of radiosensitization of [Ru(bpy)2(phen)] Cl2 complex on nasopharyngeal carcinoma cell line CNE1 and its mechanism. Materials and Methods: Nasopharyngeal carcinoma cell line CNE1 in vitro culture was divided into control group, light irradiation group (4 Gy, 6 MV photonic line), simple metal ruthenium complex treatment group (Ru group, 100 μmol/L [Ru(bpy)2(phen)]Cl2) and metal ruthenium complex combined with radiotherapy group (Combined radiotherapy group, cells were irradiated with 4 Gy and 6 MV photons at 2 days after 100 μmol/L [Ru(bpy)2(phen)]Cl2). Results: Transcriptional level of P53 gene in combined radiotherapy group was higher than that in the other groups (P<0.001). Inhibition rate of combined radiotherapy group was higher than that of Ru group and irradiation group (P<0.001). Apoptotic rate was the highest (P<0.05) in the combined radiotherapy group, and irradiation group was higher than Ru group and control group (P<0.05). Survival rate of Ru group was lower than that of control group under the same radiation dose (P<0.05), and the radiotherapy sensitization ratio was 1.227 (Dq ratio). Conclusion: [Ru(bpy)2 (phen)]Cl2 increases the sensitivity of nasopharyngeal carcinoma cell line CNE1 to X-ray, which may be related to increase of P53 gene expression.
期刊介绍:
Iranian Journal of Radiation Research (IJRR) publishes original scientific research and clinical investigations related to radiation oncology, radiation biology, and Medical and health physics. The clinical studies submitted for publication include experimental studies of combined modality treatment, especially chemoradiotherapy approaches, and relevant innovations in hyperthermia, brachytherapy, high LET irradiation, nuclear medicine, dosimetry, tumor imaging, radiation treatment planning, radiosensitizers, and radioprotectors. All manuscripts must pass stringent peer-review and only papers that are rated of high scientific quality are accepted.